James Wason
TitleCited byYear
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
S Sawcer, G Hellenthal, M Pirinen, CC Spencer, NA Patsopoulos, ...
19502011
Imaging biomarker roadmap for cancer studies
JPB O'Connor, EO Aboagye, JE Adams, HJWL Aerts, SF Barrington, ...
Nature reviews Clinical oncology 14 (3), 169-186, 2017
3452017
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor
M Ban, A Goris, ÅR Lorentzen, A Baker, T Mihalova, G Ingram, DR Booth, ...
European journal of human genetics 17 (10), 1309-1313, 2009
1392009
Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges
SS Villar, J Bowden, J Wason
Statistical Science 30 (2), 199-215, 2015
1132015
Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?
JMS Wason, L Stecher, AP Mander
Trials 15 (1), 364, 2014
742014
Optimal design of multi‐arm multi‐stage trials
J Wason, T Jaki
Statistics in Medicine 31 (30), 4269-4279, 2012
702012
Adaptive designs in clinical trials: why use them, and how to run and report them
P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ...
BMC medicine 16 (1), 29, 2018
652018
Confounding underlies the apparent month of birth effect in multiple sclerosis
B Fiddes, J Wason, A Kemppinen, M Ban, A Compston, S Sawcer
Annals of neurology 73 (6), 714-720, 2013
592013
What role for genetics in the prediction of multiple sclerosis?
S Sawcer, M Ban, J Wason, F Dudbridge
Annals of neurology 67 (1), 3-10, 2010
552010
A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials
J Wason, L Trippa
Statistics in medicine 33 (13), 2206-2221, 2014
542014
Some recommendations for multi-arm multi-stage trials
J Wason, D Magirr, M Law, T Jaki
Statistical methods in medical research 25 (2), 716-727, 2016
522016
The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma
LE Dalton, HJ Clarke, J Knight, MH Lawson, J Wason, DA Lomas, ...
British journal of cancer 108 (6), 1340-1347, 2013
462013
Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc …
EL Gerety, EM Lawrence, J Wason, H Yan, S Hilborne, J Buscombe, ...
Annals of Oncology 26 (10), 2113-2118, 2015
392015
Optimal multistage designs for randomised clinical trials with continuous outcomes
J Wason, AP Mander, SG Thompson
Statistics in Medicine, 2011
282011
Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): a pragmatic, randomised controlled, superiority trial
P Fonagy, S Butler, D Cottrell, S Scott, S Pilling, I Eisler, P Fuggle, ...
The Lancet Psychiatry, 2018
272018
Stepped wedge cluster randomized controlled trial designs: a review of reporting quality and design features
MJ Grayling, JMS Wason, AP Mander
Trials 18 (1), 33, 2017
272017
A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis
M Ban, JL McCauley, R Zuvich, A Baker, L Bergamaschi, M Cox, ...
Genes and immunity 11 (8), 660-664, 2010
272010
Admissible two‐stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis
AP Mander, J Wason, MJ Sweeting, SG Thompson
Pharmaceutical Statistics 11 (2), 91-96, 2012
262012
Confounding in association studies: month of birth and multiple sclerosis
B Fiddes, J Wason, S Sawcer
Journal of neurology 261 (10), 1851-1856, 2014
242014
Design of telehealth trials–Introducing adaptive approaches
LM Law, JMS Wason
International journal of medical informatics 83 (12), 870-880, 2014
202014
The system can't perform the operation now. Try again later.
Articles 1–20